Abstract. Tumor invasion and metastasis are complex biological processes. Matriptase and its endogenous inhibitor, hepatocyte growth factor activator inhibitor-1 (HAI-1) are involved in invasion and metastasis. To evaluate the ratio of matriptase/HAI-1 and their potential therapeutic value in ovarian cancer, HO-8910 human ovarian cancer cells and the homologous high-metastatic HO-8910PM cells were used as in vitro cellular models ovarian cancer. The invasive and metastatic abilities, and the expression of matriptase and HAI-1 in these cells were detected using scratch assays, Transwell chamber assays, reverse transcription-quantitative polymerase chain reaction, western blotting and fluorescent immunocytochemistry. Following infection with lentivirus-mediated matriptase-targeting small interfering RNA (siRNA), cell cycle progression and apoptosis were also analyzed. The migration distance and number of invading HO-8910PM cells were significantly increased compared with HO-8910 cells. HO-8910PM cells exhibited a significantly higher ratio of matriptase/HAI-1 mRNA levels compared with HO-8910 cells (0.51 vs. 0.24, ~2.2 fold increase). Compared with HO-8910 cells, the matriptase mRNA level was increased by ~3.6 fold in HO-8910PM cells, whereas the HAI-1 mRNA level was increased by ~1.7 fold. Similar increases in protein expression levels were also observed in HO-8910PM cells compared with HO-8910 cells. Migration and invasiveness were positively correlated with matriptase expression level (r=0.994, P<0.01) and the ratio of matriptase/HAI-1 (r=0.929, P<0.01). Downregulation of matriptase using siRNA resulted in inhibition of the invasive and metastatic abilities of HO-8910PM cells, cell cycle arrest in the G 0 /G 1 phase and increased apoptosis. The present study demonstrated that ovarian cancer cell metastasis and invasion were more dependent on upregulation of matriptase levels than downregulation of HAI-1. Matriptase may be a potential adjuvant therapeutic target for inhibiting ovarian cancer invasion and metastasis.
Introduction
Ovarian cancer is termed 'the silent killer' due to its lack of obvious symptoms. Annually, >225,000 ovarian cancer cases are diagnosed and it causes 125,000 mortalities (1) . Ovarian cancer is the most lethal gynecological malignancy in the United States (2) . Of the newly diagnosed cases, 70% are diagnosed at a late stage, for which the 5-year survival rate is 9-35% (3). For patients with advanced ovarian cancer, metastasis is one of the major causes of treatment failure and mortality (1) (2) (3) . Thus, researching invasive and metastatic mechanisms is important for improving ovarian cancer-associated survival and cure rates.
Tumor invasion and metastasis are complex biological processes that depend on the matrix-degrading proteolytic system (4, 5) . Matriptase (also termed suppression of tumorigenicity 14) is a protease that has attracted considerable interest among cancer biologists (6) (7) (8) . It contains a transmembrane domain, two CUB domains, four low-density lipoprotein-receptor domains and a serine protease domain (7, 9) . It is expressed in a wide range of epithelial tissues, including the epidermis, gastrointestinal tract and respiratory tract, and in endothelial, neural and white blood cells (10) (11) (12) .
Currently, few published studies have attempted to address the importance of this protein in ovarian carcinoma. However, there are different conclusions regarding the function of matriptase in ovarian cancer. Tanimoto et al (10) reported that increased matriptase expression is associated with early-stage ovarian cancer and longer patient survival, suggesting that matriptase is a favorable prognostic marker for ovarian cancer. Conversely, Jin et al (13) reported that elevated expression of matriptase in serous adenocarcinoma was significantly associated with tumor aggressiveness. The effect of matriptase in ovarian carcinoma remains unclear, and the conflicting conclusions regarding matriptase may be associated with the varying expression of its endogenous inhibitor, hepatocyte growth factor activator inhibitor-1 (HAI-1) (14) . Oberst et al (15) demonstrated that an imbalance of matriptase and HAI-1 is observed in advanced ovarian cancer tissues. Furthermore, Vogel et al (16) reported that the matriptase mRNA level was lower in cancer tissues compared with normal tissue from healthy individuals, whereas the ratio of matriptase/HAI-1 mRNA was higher in colorectal cancer adenomas and carcinomas compared with corresponding tissue from control individuals. These previous investigations indicate that the ratio of matriptase/HAI-1 involved in the biological behavior of cancer cell. A previous study demonstrated that the in vitro invasive and metastatic abilities of ovarian cancer cells are correlated with the expression level of matriptase (17) . The current study aimed to determine whether this correlation is associated with the expression of matriptase or HAI-1, or with the ratio of matriptase/HAI-1. Furthermore, the study aimed to demonstrate the potential effect of matriptase inhibition as an adjuvant therapeutic. (20) .
Decreasing the ratio of matriptase/HAI-1 by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer

Materials and methods
Cells
Fluorescent immunocytochemistry. Cells were seeded at 1.0x10 5 cells/well were seed on the glass coverslips then placed in a 12-well-plate, and cultured overnight. The cells were rinsed with phosphate-buffered saline (PBS), and fixed with 4% paraformaldehyde for 10 min, followed by goat serum (OriGene Technologies, Inc., Beijing, China)blocking for 30 min. Next, the cells were incubated with rabbit-anti-matripase polyclonal antibody (cat. no. ab28266; 1:500; Abcam, Cambridge, UK) at 4°C for overnight. Subsequent to incubation, cells were rinsed with PBS twice and incubated with FITC-labeled goat-anti-rabbit antibody (cat. no. BA1110; 1:50; Boster Bio, Wuhan, China) for 1 h. To detect the nucleus of cells, they were washed by PBS for 5 min, and cell nuclei were stained with 4',6-diamidino-2phenylindole at 1:1000 dilution for 5 min. Serum-free DMEM medium was used as a negative control. Subsequent to the discarding of the medium, the cells were analysed using a confocal scanning microscope (Leica Microsystems GmbH, Solms, Germany). The image was analysed by LAS AF lite software (21) . For the slides, each quadrant section and the middle section (3 fields in total) were observed at random at magnification, x 100, 20 cells/field were used to calculate the intensity of green fluorescence signal and recorded as the mean ± standard deviation (21) .
Cellular scratch assay. The horizontal migration of cells was assessed by a scratch assay (22) . Cells were seeded at a density of 5.0x10 5 cells/well, then imaged at x40 magnification with an Olympus IX70 inverted fluorescence microscope (Olympus Corporation, Tokyo, Japan) at 0 and 24 h post-scratching. Image ProExpress C software 5.1 (Olympus Corporation) was used to measure the change of the cell distance between the scratches. The average horizontal migration rate was calculated using the following formula: (Width 0 h -width 24 h )/width 0 h x 100.
Transwell chamber assay. The cellular invasive capacity was determined using the Matrigel invasion chamber assay as previous reported (23) . Cells were seeded at a density of 5.0x10 5 cells/well. The number of cells on the underside of the filter was determined by counting cells in 5 random fields from 3 filters for each treatment at x200 magnification with an inverted microscope (Olympus Corporation).
Western blotting. Whole-cell protein was extracted according to the protocol provided with the Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Inc.). The protein content was determined using an enzyme-linked immunosorbent assay. Whole-cell protein (100 µg) was loaded on an 8% polyacrylamide gel. Proteins were blotted onto nitrocellulose membranes. The blots were washed in phosphate-buffered saline (PBS) and incubated in blocking buffer [1X PBS, 0.1% Tween-20, 5% I-Block (Thermo Fisher Scientific, Inc.)] at 20˚C for 1 h. Membranes were incubated overnight at 20˚C with a polyclonal rabbit matriptase antibody (1:1,000 dilution; cat. no. ab28266; Abcam) or a monoclonal rabbit HAI-1 antibody (1:2,000 dilution; cat. no. ab189511; Abcam) in blocking buffer, followed by incubation with an alkaline phosphatase-conjugated anti-rabbit secondary antibody (cat. no. BA0632; 1:1,000; Boster Bio) at room temperature for 10 min. Bands were visualized using the CDP-Star luminescence system (Sigma-Aldrich, St. Louis, MO, USA).
Lentivirus-mediated small interfering RNA (siRNA) construction and infection. Three pairs of complementary oligonucleotides target matriptase gene (GenBank accession no. NM_021978) were designed as follows: Ma-siRNA-1, CCG GCT TCT TAG CTG AATA; Ma-siRNA-2, TGT CCA GAA GGT CTT CAAT; and Ma-siRNA-3, ACG AGA AAG TGG AAT GGCTT. These stem-loop oligonucleotides were synthesized and cloned into a lentivirus-based vector carrying the green fluorescent protein (GFP) gene (cat. no. GV115; GeneChem Co., Ltd., Shanghai, China). A universal sequence (TTC TCC GAA CGT GTC ACGT) was used as a negative control (NC) for RNA interference. The siRNA and NC lentiviral constructs were prepared as previously described (24) and used to infect HO-8910PM cells at multiplicities of infection (MOIs) of 20 (low) and 80 (high). The siRNA with the highest silencing efficiency was used for subsequent experiments.
Cellular DNA and apoptosis analysis. For flow cytometric analysis, the harvested cell pellets of HO-8910PM, and transfected HO-8910PM-NC and HO-8910PM-SI were fixed with pre-cooled 70% ethanol and stained with propidium iodide (100 µg/ml RNase in PBS) at 37˚C for 30 min. The cell cycle distribution was then determined as previously described (25) . Apoptosis was detected using the Annexin-V-FLUOS staining kit (Roche Diagnostics GmbH) according to the manufacturer's protocol. Fluorescein was measured using a FACSCanto II flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).
Statistical analysis.
All the experiments were performed in triplicate. Statistical analyses were performed using the average results of three repeated experiments under identical conditions. Numerical data are presented as the mean ± standard deviation. The differences between two means were compared by Student's t-test and related parameters were analyzed using Pearson's correlation analysis. A one-way analysis of variance was used for multiple comparisons of groups. Data were analyzed using SPSS software 15.0 for Windows (SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference. Association of invasive and metastatic activity with the expression of matriptase. To evaluate the potential association of matriptase expression with the invasive and metastatic activity of ovarian cancer cells, Pearson's correlation analysis was performed. The metastasis and invasiveness of the ovarian cancer cells were positively correlated with matriptase mRNA expression levels (r=0.994 and r=0.965, respectively; P<0.01) and matriptase protein expression levels (r=0.976 and r=0.961, respectively; P<0.05). The metastasis and invasiveness were also positively correlated with the ratio of matriptase/HAI-1 (r=0.929 and r=0.912, respectively; P<0.01). However, metastasis and invasion were not significantly correlated with the expression of HAI-1 (P>0.05).
Results
Different invasive and metastatic activity in HO-
Suppression of matriptase expression in HO-8910PM cells.
Three lentivirus-mediated siRNAs targeting matriptase were constructed and used to infect HO-8910PM cells at high and low MOIs (Fig. 3A) . Compared with NC, matriptase mRNA levels in HO-8910PM cells were decreased by 19.63, 89.72 and 32.43% by Ma-siRNA-1, Ma-siRNA-2, and Ma-siRNA-3, respectively (Fig. 3B) . Additionally, western blot analysis demonstrated that Ma-siRNA-2 significantly reduced the matriptase protein expression level compared with NC (P<0.01; Fig. 3C ). The siRNA inhibited matriptase expression but did not affect HAI-1 levels. The HO-8910PM cells infected with Ma-siRNA-2, which induced the greatest inhibition of matriptase levels, were termed HO-8910PM-SI2 and selected for further analysis. 
Inhibition of the invasiveness and metastatic ability of
Discussion
Despite clinical effort, metastatic ovarian cancer often inevitably progresses to eventually cause mortality (25) . Several previous reports suggest that matriptase is involved in the initiation of epithelial cell carcinogenesis (12, (26) (27) (28) . Furthermore, matriptase may also be important for cell invasiveness and metastasis (29, 30 ). In the current study, the human ovarian cancer cell HO-8910 and its homologous highly metastatic clone HO-8910PM were used to assess the 
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An explanation for these differences may be that ovarian carcinoma subtypes exhibit different biological behaviors (3, 33) . Notably, breast cancer also exhibits a similar diversity in matriptase expression and function (34, 35) . Additionally, the variation may be associated with the expression of HAI-1. Oberst et al (15) reported that the ratio of matriptase/HAI-1 was increased in advanced-stage ovarian cancers. A similar increased ratio of matriptase/HAI-1 was also reported in advanced stage color cancer (16, 36) . Upregulation of the ratio is dependent on increased expression of matriptase or decreased the expression of HAI-1. To maximize control of the other potential factors that may affect invasiveness and metastatic ability, the current study used a pair of homologous ovarian cell lines with similar genetic backgrounds. The results of the present study demonstrated that the increasing ratio of matriptase/HAI-1 (~2 fold in HO-8910PM) was predominantly dependent on the relative increased expression of matriptase (~3.6 fold in mRNA and ~2.3 fold in protein), not the decreased expression of HAI-1, as the mRNA and protein levels of the latter were also increased by ~1.7 and 1.2 fold, respectively. Correlation analyses demonstrated that the different metastatic and invasive abilities of the ovarian cancer cells were positively correlated with the ratio of matriptase/HAI-1 and the expression level of matriptase, but not with the expression level of HAI-1. Furthermore, RT-qPCR and western blotting demonstrated that siRNA infection significantly decreased the matriptase expression level in HO-8910PM cells, resulting in significantly decreased in the HO-8910PM cell invasion and migration. Thus, it is concluded that the ovarian cancer cell metastasis and invasion was dependent on the activation of matriptase, but not on HAI-1.
The present study concluded that the ratio of matriptase/HAI-1 is directly and positively correlated with cellular invasion and metastasis, and the ratio is predominantly altered by changes in the expression level of matriptase. Thus, matriptase may be a potential therapeutic target. Results from flow cytometric analysis demonstrated that HO-8910PM-SI2 cells exhibited a greater proportion of G 0 /G 1 phase cells and smaller proportion of G 2 /M phase cells compared with HO-8910PM and HO-8910PM-NC cells, indicating that matriptase downregulation results in ovarian cancer cell cycle arrest. Although the cellular apoptosis percentage in HO-8910PM-SI2 cells was significantly increased compared with HO-8910PM and HO-8910PM-NC cells, the apoptosis induced by siRNA is limited compared with cytotoxic drugs, such as cisplatin, which typically induce apoptosis in ~30% of cells at 10 µM (37) . Other previous studies demonstrated that inhibition of matriptase enhances the treatment of hepatocellular carcinoma, breast cancer and prostate cancer (38, 39) . In ovarian cancer, matriptase downregulation results in the inhibition of intraperitoneal tumor growth in nude mice and prolongs the mean survival of tumor-bearing mice (30) . In the current study, as a candidate therapeutic target, matriptase suppression resulted in cell cycle arrest in the G 0 /G 1 phase and induced limited apoptosis. Thus, targeting this protein may slow the progression of metastatic ovarian cancer, rather than providing a cure. Matriptase may be useful as target for adjuvant therapy for classical cytotoxic chemotherapy to limit cellular invasion and metastasis.
In summary, the findings of the current study suggest that the increased ratio of matriptase/HAI-1 is predominantly dependent on the increased expression level of matriptase, and it is a reliable indicator that reflects the aggressive nature of ovarian cancer cells. Matriptase may potentially be an adjuvant therapeutic target for inhibiting ovarian cancer invasion and metastasis.
